X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ketorolac (NTM-001) is a novel, alcohol-free formulation of ketorolac in a convenient, ready-to-use, pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Neurology Product Name: NTM-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Nuance Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
This data further demonstrates NTM-006’s analgesic and anti-inflammatory activity in a variety of animal models, predictive of analgesic efficacy against chronic pain.
Lead Product(s): NTM-006
Therapeutic Area: Neurology Product Name: JNJ-10450232
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
The data to be presented include the final study results from four cohorts of a randomized, controlled clinical trial evaluating NTM-001, a novel, alcohol-free 24-hour continuous infusion formulation of the well-established potent NSAID analgesic ketorolac tromethamine.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Neurology Product Name: NTM-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
The licensing agreement provides Nuance with the exclusive rights to develop and commercialize Neumentum’s novel ketorolac for IV infusion (NTM-001) in China.
Lead Product(s): Ketorolac Trometamol
Therapeutic Area: Neurology Product Name: NTM-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nuance Biotech
Deal Size: $53.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement October 21, 2020
Details:
Neumentum will present two posters with data on NTM-006, a new chemical entity (NCE) non-opioid, non-NSAID analgesic candidate that may have the potential to replace opioids, at PAINWeek 2020 Live Virtual Conference, being held on September 11-13, 2020.
Lead Product(s): NTM-006
Therapeutic Area: Neurology Product Name: JNJ-10450232
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
